Multisectoral resilience to funding cuts in Guatemala
In 2025, cuts in international support for the HIV response in Guatemala and a reduced HIV allocation from the Global Fund caused immediate challenges for the HIV response. Some services were curtailed or discontinued altogether in clinics affected by the cuts, and remaining service providers struggled to absorb clients who had lost their service access. Furthermore, a substantial portion of the personnel at HIV comprehensive care units and community outreach workers that help facilitate and…
South Africa charts a new frontier by rolling out a twice-yearly injection which is almost 100% effective in preventing HIV
UNAIDS welcomes the announcement of new deals to make new HIV prevention medicines available and affordable for people in need
UNAIDS strongly welcomes the announcement of two new agreements to advance progress in stopping new HIV infections. UNAIDS estimates show that 1.3 million people were infected with HIV in 2024 far higher than the target of 370,000 by 2025. Lenacapavir, produced by US company Gilead, is a revolutionary new medicine that prevents HIV infection with injections just twice a year.
UNAIDS welcomes new WHO guidelines on Lenacapavir
Lenacapavir–a long-acting, six-monthly injectable antiretroviral medicine manufactured by Gilead Sciences–is now recommended by the World Health Organization as an additional HIV prevention choice as part of combination HIV prevention approaches.
Cambodia becomes the second country in the Asia Pacific to offer long-acting PrEP
Borey and Sophia are among the first clients in Cambodia to begin long-acting injectable Cabotegravir (CAB-LA), a PrEP formulation administered every two months. With this initiative, Cambodia has become a frontrunner in the Asia Pacific region to roll out long-acting PrEP.
Global leaders convene to accelerate access to long-acting HIV prevention technologies amidst funding cuts
The global response to HIV has reached a crucial juncture. Groundbreaking scientific advances, including the development of long-acting HIV prevention technologies like lenacapavir and cabotegravir, offer a transformative opportunity to curb the epidemic.
US foreign aid cuts puts the lives of people who use drugs at risk
Godfrey Swai is shaken. Since the end of January, the US aid funding cuts have meant that he can only afford for his staff to work a couple of hours twice a week compared to a full five days.
HIV Epidemic in Mozambique and US Government Contribution (PEPFAR)
HIV Epidemic in Mozambique and US Government Contribution (PEPFAR)
UNAIDS urges countries to invest in HIV prevention as key to ending AIDS
Despite proven effectiveness, UNAIDS is alarmed by a decrease in condom use in several countries
A crisis unfolding: hard-won progress in Ethiopia’s HIV response at risk
Ethiopia has made significant progress in its HIV response in recent years and is on track to reach the UNAIDS 95-95-95 targets with 90% of people living with HIV in the country being aware of their HIV status; 94% of those diagnosed with HIV receiving antiretroviral (ARV) therapy; and 96% of people on ARV therapy achieving viral suppression. But now, that progress is at risk. The recent pause in United States foreign assistance poses a direct threat to the lives and well-being of thousands of…
